Published in J Virol on August 01, 1992
Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci U S A (2006) 6.82
Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag). Proc Natl Acad Sci U S A (2001) 5.83
Self-assembly in vitro of purified CA-NC proteins from Rous sarcoma virus and human immunodeficiency virus type 1. J Virol (1995) 5.21
Functional surfaces of the human immunodeficiency virus type 1 capsid protein. J Virol (2003) 4.47
Structural organization of authentic, mature HIV-1 virions and cores. EMBO J (2003) 4.32
Mutations in the N-terminal region of human immunodeficiency virus type 1 matrix protein block intracellular transport of the Gag precursor. J Virol (1993) 4.20
X-ray structures of the hexameric building block of the HIV capsid. Cell (2009) 4.08
The spacer peptide between human immunodeficiency virus capsid and nucleocapsid proteins is essential for ordered assembly and viral infectivity. J Virol (1995) 3.80
Virus maturation by budding. Microbiol Mol Biol Rev (1998) 3.78
Assembly, processing, and infectivity of human immunodeficiency virus type 1 gag mutants. J Virol (1993) 3.75
The structural biology of HIV assembly. Curr Opin Struct Biol (2008) 3.71
Role of the major homology region of human immunodeficiency virus type 1 in virion morphogenesis. J Virol (1994) 3.48
Functional domains of the capsid protein of human immunodeficiency virus type 1. J Virol (1994) 3.47
In vitro assembly properties of human immunodeficiency virus type 1 Gag protein lacking the p6 domain. J Virol (1999) 3.34
Assembly properties of the human immunodeficiency virus type 1 CA protein. J Virol (2004) 3.09
Infectivity of Moloney murine leukemia virus defective in late assembly events is restored by late assembly domains of other retroviruses. J Virol (2000) 2.98
Requirements for incorporation of Pr160gag-pol from human immunodeficiency virus type 1 into virus-like particles. J Virol (1993) 2.69
Atomic-level modelling of the HIV capsid. Nature (2011) 2.41
Relationship between human immunodeficiency virus type 1 Gag multimerization and membrane binding. J Virol (2000) 2.07
Phenotypic characterization of insertion mutants of the human immunodeficiency virus type 1 Gag precursor expressed in recombinant baculovirus-infected cells. J Virol (1994) 1.99
Characterization of Rous sarcoma virus Gag particles assembled in vitro. J Virol (2001) 1.85
Efficient in vivo and in vitro assembly of retroviral capsids from Gag precursor proteins expressed in bacteria. J Virol (1995) 1.81
Detection of a trimeric human immunodeficiency virus type 1 Gag intermediate is dependent on sequences in the matrix protein, p17. J Virol (1998) 1.66
Domain-swapped dimerization of the HIV-1 capsid C-terminal domain. Proc Natl Acad Sci U S A (2007) 1.66
Interactions between HIV-1 Gag molecules in solution: an inositol phosphate-mediated switch. J Mol Biol (2006) 1.65
Three-dimensional structure of the M-MuLV CA protein on a lipid monolayer: a general model for retroviral capsid assembly. EMBO J (2003) 1.58
Rous sarcoma virus Gag protein-oligonucleotide interaction suggests a critical role for protein dimer formation in assembly. J Virol (2002) 1.56
Kinetic analysis of the role of intersubunit interactions in human immunodeficiency virus type 1 capsid protein assembly in vitro. J Virol (2002) 1.55
Association of human immunodeficiency virus type 1 gag with membrane does not require highly basic sequences in the nucleocapsid: use of a novel Gag multimerization assay. J Virol (2005) 1.55
Structural analysis of membrane-bound retrovirus capsid proteins. EMBO J (1997) 1.48
Nucleic acid binding and chaperone properties of HIV-1 Gag and nucleocapsid proteins. Nucleic Acids Res (2006) 1.47
Role of the Rous sarcoma virus p10 domain in shape determination of gag virus-like particles assembled in vitro and within Escherichia coli. J Virol (2000) 1.40
Disulfide bond stabilization of the hexameric capsomer of human immunodeficiency virus. J Mol Biol (2010) 1.35
Mutation of dileucine-like motifs in the human immunodeficiency virus type 1 capsid disrupts virus assembly, gag-gag interactions, gag-membrane binding, and virion maturation. J Virol (2006) 1.35
Compensatory substitutions restore normal core assembly in simian immunodeficiency virus isolates with Gag epitope cytotoxic T-lymphocyte escape mutations. J Virol (2006) 1.33
HIV-1 capsid protein forms spherical (immature-like) and tubular (mature-like) particles in vitro: structure switching by pH-induced conformational changes. Biophys J (2001) 1.32
Effect of macromolecular crowding agents on human immunodeficiency virus type 1 capsid protein assembly in vitro. J Virol (2005) 1.32
Analysis of minimal human immunodeficiency virus type 1 gag coding sequences capable of virus-like particle assembly and release. J Virol (1998) 1.32
Nucleocapsid promotes localization of HIV-1 gag to uropods that participate in virological synapses between T cells. PLoS Pathog (2010) 1.31
Mutations in the Ty3 major homology region affect multiple steps in Ty3 retrotransposition. J Virol (1996) 1.30
Flexibility in HIV-1 assembly subunits: solution structure of the monomeric C-terminal domain of the capsid protein. Biophys J (2007) 1.29
Human immunodeficiency virus type 1 capsid formation in reticulocyte lysates. J Virol (1996) 1.27
Structural interactions between retroviral Gag proteins examined by cysteine cross-linking. J Virol (1995) 1.25
Assembly of human immunodeficiency virus (HIV) antigens on bacteriophage T4: a novel in vitro approach to construct multicomponent HIV vaccines. J Virol (2006) 1.24
Human immunodeficiency virus type 1 MA deletion mutants expressed in baculovirus-infected cells: cis and trans effects on the Gag precursor assembly pathway. J Virol (1995) 1.24
Elimination of protease activity restores efficient virion production to a human immunodeficiency virus type 1 nucleocapsid deletion mutant. J Virol (2003) 1.21
A molecular determinant of human immunodeficiency virus particle assembly located in matrix antigen p17. J Virol (1995) 1.13
HIV-1 uncoating: connection to nuclear entry and regulation by host proteins. Virology (2014) 1.12
Charged assembly helix motif in murine leukemia virus capsid: an important region for virus assembly and particle size determination. J Virol (2003) 1.11
A molecular switch required for retrovirus assembly participates in the hexagonal immature lattice. EMBO J (2008) 1.09
Assembly of retrovirus capsid-nucleocapsid proteins in the presence of membranes or RNA. J Virol (2000) 1.08
Conservation of a stepwise, energy-sensitive pathway involving HP68 for assembly of primate lentivirus capsids in cells. J Virol (2004) 1.08
Second-site suppressors of HIV-1 capsid mutations: restoration of intracellular activities without correction of intrinsic capsid stability defects. Retrovirology (2012) 1.06
Analysis of Mason-Pfizer monkey virus Gag domains required for capsid assembly in bacteria: role of the N-terminal proline residue of CA in directing particle shape. J Virol (2000) 1.06
Characterization of the in vitro HIV-1 capsid assembly pathway. J Mol Biol (2009) 1.04
Molecular organization of Mason-Pfizer monkey virus capsids assembled from Gag polyprotein in Escherichia coli. J Virol (2002) 1.02
Tripeptide interference with human immunodeficiency virus type 1 morphogenesis. Antimicrob Agents Chemother (2002) 1.02
The solution structure of the bovine leukaemia virus matrix protein and similarity with lentiviral matrix proteins. EMBO J (1996) 1.01
Structural and dynamical characterization of tubular HIV-1 capsid protein assemblies by solid state nuclear magnetic resonance and electron microscopy. Protein Sci (2010) 1.01
The interdomain linker region of HIV-1 capsid protein is a critical determinant of proper core assembly and stability. Virology (2011) 0.99
Homo-oligomerization of the porcine reproductive and respiratory syndrome virus nucleocapsid protein and the role of disulfide linkages. J Virol (2003) 0.99
Cyclophilin A-induced alterations of human immunodeficiency virus type 1 CA protein in vitro. J Virol (1997) 0.99
Distinct roles for nucleic acid in in vitro assembly of purified Mason-Pfizer monkey virus CANC proteins. J Virol (2006) 0.98
Simulated self-assembly of the HIV-1 capsid: protein shape and native contacts are sufficient for two-dimensional lattice formation. Biophys J (2011) 0.98
Design of in vitro symmetric complexes and analysis by hybrid methods reveal mechanisms of HIV capsid assembly. J Mol Biol (2011) 0.97
Effects of Gag mutation and processing on retroviral dimeric RNA maturation. J Virol (2006) 0.94
Characterization of the invariable residue 51 mutations of human immunodeficiency virus type 1 capsid protein on in vitro CA assembly and infectivity. Retrovirology (2007) 0.92
The Mason-Pfizer monkey virus internal scaffold domain enables in vitro assembly of human immunodeficiency virus type 1 Gag. J Virol (2002) 0.92
Retroviral capsid assembly: a role for the CA dimer in initiation. J Mol Biol (2009) 0.91
Basic residues in the nucleocapsid domain of Gag are critical for late events of HIV-1 budding. J Virol (2010) 0.91
Higher-order structure of the Rous sarcoma virus SP assembly domain. J Virol (2014) 0.89
Proton-driven assembly of the Rous Sarcoma virus capsid protein results in the formation of icosahedral particles. J Biol Chem (2010) 0.88
Budding of retroviruses utilizing divergent L domains requires nucleocapsid. J Virol (2012) 0.86
A retroviral chimeric capsid protein reveals the role of the N-terminal β-hairpin in mature core assembly. J Mol Biol (2011) 0.84
Therapeutic effect of Gag-nuclease fusion protein on retrovirus-infected cell cultures. J Virol (1996) 0.83
In vitro assembly of virus-like particles of a gammaretrovirus, the murine leukemia virus XMRV. J Virol (2011) 0.83
TY3 GAG3 protein forms ordered particles in Escherichia coli. Virology (2007) 0.83
The maturational refolding of the β-hairpin motif of equine infectious anemia virus capsid protein extends its helix α1 at capsid assembly locus. J Biol Chem (2012) 0.81
Basic residues in the matrix domain and multimerization target murine leukemia virus Gag to the virological synapse. J Virol (2013) 0.81
Rationally designed interfacial peptides are efficient in vitro inhibitors of HIV-1 capsid assembly with antiviral activity. PLoS One (2011) 0.81
Coarse-grained simulation reveals key features of HIV-1 capsid self-assembly. Nat Commun (2016) 0.80
Murine leukemia virus Gag localizes to the uropod of migrating primary lymphocytes. J Virol (2014) 0.79
HIV Assembly and Budding: Ca(2+) Signaling and Non-ESCRT Proteins Set the Stage. Mol Biol Int (2012) 0.79
Selection of recombinant, library-derived antibody fragments against p24 for human immunodeficiency virus type 1 diagnostics. Clin Diagn Lab Immunol (1998) 0.79
A second-site suppressor significantly improves the defective phenotype imposed by mutation of an aromatic residue in the N-terminal domain of the HIV-1 capsid protein. Virology (2006) 0.79
Biophysical characterization of the feline immunodeficiency virus p24 capsid protein conformation and in vitro capsid assembly. PLoS One (2013) 0.79
The N-terminus of murine leukaemia virus p12 protein is required for mature core stability. PLoS Pathog (2014) 0.78
Tsg101 regulates PI(4,5)P2/Ca(2+) signaling for HIV-1 Gag assembly. Front Microbiol (2014) 0.78
Comparison of Biochemical Properties of HIV-1 and HIV-2 Capsid Proteins. Front Microbiol (2017) 0.78
Microfluidic devices with templated regular macroporous structures for HIV viral capture. Analyst (2016) 0.78
Analysis of the mechanical properties of wild type and hyperstable mutants of the HIV-1 capsid. Retrovirology (2016) 0.77
HIV p24 as scaffold for presenting conformational HIV Env antigens. PLoS One (2012) 0.77
Major Variations in HIV-1 Capsid Assembly Morphologies Involve Minor Variations in Molecular Structures of Structurally Ordered Protein Segments. J Biol Chem (2016) 0.75
The effect of chemical chaperones on the assembly and stability of HIV-1 capsid protein. PLoS One (2013) 0.75
Kinetics of Surface-Driven Self-Assembly and Fatigue-Induced Disassembly of a Virus-Based Nanocoating. Biophys J (2017) 0.75
Determining interdomain structure and dynamics of a retroviral capsid protein in the presence of oligomerization: implication for structural transition in capsid assembly. Biochemistry (2013) 0.75
Novel In Vitro Screening System Based on Differential Scanning Fluorimetry to Search for Small Molecules against the Disassembly or Assembly of HIV-1 Capsid Protein. Front Microbiol (2017) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A (1979) 365.71
Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1989) 12.54
Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A (1988) 10.77
Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature (1988) 10.69
Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc Natl Acad Sci U S A (1991) 10.05
Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell (1989) 9.68
Form, function, and use of retroviral gag proteins. AIDS (1991) 9.24
Myristoylation-dependent replication and assembly of human immunodeficiency virus 1. Proc Natl Acad Sci U S A (1990) 8.23
Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins. Virology (1987) 7.92
Characterization of Moloney murine leukemia virus mutants with single-amino-acid substitutions in the Cys-His box of the nucleocapsid protein. J Virol (1989) 5.47
Noninfectious human immunodeficiency virus type 1 mutants deficient in genomic RNA. J Virol (1990) 5.45
Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J Virol (1989) 5.15
Structural characterization of reverse transcriptase and endonuclease polypeptides of the acquired immunodeficiency syndrome retrovirus. J Virol (1986) 5.05
ATP-dependent assembly of double hexamers of SV40 T antigen at the viral origin of DNA replication. Nature (1989) 4.64
Chemical probes of extended biological structures: synthesis and properties of the cleavable protein cross-linking reagent [35S]dithiobis(succinimidyl propionate). J Mol Biol (1976) 3.77
Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor. Proc Natl Acad Sci U S A (1987) 3.72
Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein. J Virol (1991) 3.62
Polymorphism in the assembly of polyomavirus capsid protein VP1. Biophys J (1989) 2.74
N-hydroxysulfosuccinimide active esters: bis(N-hydroxysulfosuccinimide) esters of two dicarboxylic acids are hydrophilic, membrane-impermeant, protein cross-linkers. Biochemistry (1982) 2.63
Murine leukemia virus morphogenesis: cleavage of P70 in vitro can be accompanied by a shift from a concentrically coiled internal strand ("immature") to a collapsed ("mature") form of the virus core. Proc Natl Acad Sci U S A (1977) 2.22
Processing of in vitro-synthesized gag precursor proteins of human immunodeficiency virus (HIV) type 1 by HIV proteinase generated in Escherichia coli. J Virol (1988) 2.09
Structural studies of retroviruses: characterization of oligomeric complexes of murine and feline leukemia virus envelope and core components formed upon cross-linking. J Virol (1979) 1.90
Chemical crosslinking of proteins in avian sarcoma and leukemia viruses. Virology (1980) 1.83
Localization of lipid-protein and protein-protein interactions within the murine retrovirus gag precursor by a novel peptide-mapping technique. J Biol Chem (1983) 1.78
Site-directed mutation affecting polyomavirus capsid self-assembly in vitro. Nature (1987) 1.75
Molecular biology of HIV: new insights into the virus life-cycle. AIDS (1989) 1.68
Electron microscopy of human immunodeficiency virus. J Gen Virol (1988) 1.67
Expression in Escherichia coli and purification of human immunodeficiency virus type 1 capsid protein (p24). AIDS Res Hum Retroviruses (1990) 1.40
A new cleavable reagent for cross-linking and reversible immobilization of proteins. Biochem Biophys Res Commun (1979) 1.40
Deletion of sequences upstream of the proteinase improves the proteolytic processing of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1991) 1.33
Antiviral agents targeted to interact with viral capsid proteins and a possible application to human immunodeficiency virus. Proc Natl Acad Sci U S A (1988) 1.22
Virus structure: high-resolution perspectives. Adv Virus Res (1983) 1.18
Physical and chemical properties of Moloney murine leukemia virus p30 protein: a major core structural component exhibiting high helicity and self-association. J Mol Biol (1976) 1.17
Preparation and crystallization of a human immunodeficiency virus p24-Fab complex. Proc Natl Acad Sci U S A (1990) 1.13
A possible homology between immunodeficiency virus p24 core protein and picornaviral VP2 coat protein: prediction of HIV p24 antigenic sites. EMBO J (1989) 1.08
Disk aggregates of tobacco mosaic virus protein in solution: electron microscopy observations. Biochemistry (1986) 0.99
Location of epitopes on the major core protein p24 of human immunodeficiency virus. J Gen Virol (1990) 0.95
Structure of a T = 1 aggregate of alfalfa mosaic virus coat protein seen at 4.5 A resolution. J Mol Biol (1983) 0.93
Expression and purification of p24, the core protein of HIV, using a baculovirus-insect cell expression system. AIDS (1990) 0.93
Further studies of HIV morphology by negative staining. AIDS (1988) 0.87
An electron microscopic investigation of the structure of alfalfa mosaic virus. J Mol Biol (1981) 0.84
Negative staining of protein macromolecules: a simple rapid method. J Ultrastruct Res (1979) 0.82
Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag). Proc Natl Acad Sci U S A (2001) 5.83
Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells. J Virol (2001) 2.17
Processing of in vitro-synthesized gag precursor proteins of human immunodeficiency virus (HIV) type 1 by HIV proteinase generated in Escherichia coli. J Virol (1988) 2.09
Activity of purified biosynthetic proteinase of human immunodeficiency virus on natural substrates and synthetic peptides. Proc Natl Acad Sci U S A (1989) 1.81
Tsg101 control of human immunodeficiency virus type 1 Gag trafficking and release. J Virol (2003) 1.56
Expression in Escherichia coli and purification of human immunodeficiency virus type 1 capsid protein (p24). AIDS Res Hum Retroviruses (1990) 1.40
HIV-1 capsid protein forms spherical (immature-like) and tubular (mature-like) particles in vitro: structure switching by pH-induced conformational changes. Biophys J (2001) 1.32
Liquid and solid potassium chloride: bioavailability and safety. Pharmacotherapy (1985) 1.21
Membrane-induced alterations in HIV-1 Gag and matrix protein-protein interactions. J Mol Biol (1998) 1.17
Release of N2,3-ethanoguanine from haloethylnitrosourea-treated DNA by Escherichia coli 3-methyladenine DNA glycosylase II. Carcinogenesis (1991) 1.14
Preparation and crystallization of a human immunodeficiency virus p24-Fab complex. Proc Natl Acad Sci U S A (1990) 1.13
A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Ann Oncol (2013) 1.11
The major homology region of the HIV-1 gag precursor influences membrane affinity. Biochemistry (1996) 1.07
Direct interaction of all-trans-retinoic acid with protein kinase C (PKC). Implications for PKC signaling and cancer therapy. J Biol Chem (2000) 1.05
Comparison of models describing the thermal lens effect. Appl Opt (1984) 1.04
Effect of the prostaglandin synthetase inhibitor indomethacin on 7,12-dimethylbenz(a)anthracene-induced mammary tumorigenesis in rats fed different levels of fat. Cancer Res (1983) 1.02
Review of diclofenac and evaluation of its place in therapy as a nonsteroidal antiinflammatory agent. Drug Intell Clin Pharm (1988) 1.00
Cyclophilin A-induced alterations of human immunodeficiency virus type 1 CA protein in vitro. J Virol (1997) 0.99
Spectral analysis and tryptic susceptibility as probes of HIV-1 capsid protein structure. Virology (1994) 0.98
Requirement of essential fatty acid for mammary tumorigenesis in the rat. Cancer Res (1985) 0.97
Evaluation of the effectiveness of two support surfaces following myocutaneous flap surgery. Adv Wound Care (1995) 0.90
Methylation of reovirus oligonucleotides in vivo and in vitro. Virology (1977) 0.90
Corneal cell culture and organ storage. Trans Ophthalmol Soc U K (1986) 0.90
A consensus conference on complex biologics and low molecular weight heparins. Int Angiol (2010) 0.86
Release of 7-alkylguanines from N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea-modified DNA by 3-methyladenine DNA glycosylase II. Cancer Res (1991) 0.83
Experimental ulcerative herpetic keratitis. IV. Preliminary observations on the efficacy of a herpes simplex subunit vaccine. Br J Ophthalmol (1981) 0.82
Formation and Reactivity of the Osmium(IV)-Cyanoimido Complex [Os(IV) (bpy)(Cl)3 (NCN)](-). Angew Chem Int Ed Engl (2001) 0.82
Activation of prostate-specific antigen precursor (pro-PSA) by prostin, a novel human prostatic serine protease identified by degenerate PCR. Biochemistry (2001) 0.82
2-Chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts. Cancer Res (1997) 0.81
Sprouty 2 binds ESCRT-II factor Eap20 and facilitates HIV-1 gag release. J Virol (2011) 0.81
Ascorbic acid promotes recovery of cellular functions following toxicant-induced injury. Toxicol Appl Pharmacol (2000) 0.81
Stimulation of CD4+ T lymphocytes by allogeneic MHC peptides presented on autologous antigen-presenting cells. Evidence of the indirect pathway of allorecognition in some strain combinations. Transplantation (1992) 0.81
A rat class I cDNA clone with an Alu-like sequence and mapping to two genes in RT1.C/E. Immunogenetics (1990) 0.80
Conservation and modification of the pyrimidine-rich reovirus oligonucleotides after infection. Virology (1979) 0.79
Phenotype and differentiation potential of a novel rat tracheal epithelial cell line. Am J Respir Cell Mol Biol (1995) 0.79
Leuprolide: a gonadotropin-releasing hormone analog for the palliative treatment of prostatic cancer. Drug Intell Clin Pharm (1986) 0.78
Tamoxifen alters the localization of F-actin and alpha 5/beta 1-integrin fibronectin receptors in human endometrial stromal cells and carcinoma cells. Pathobiology (1997) 0.78
Ethotoin in seizures of childhood and adolescence. Neurology (1984) 0.78
Both extraneuronal monoamine transporter and O(6)-methylguanine-DNA methyltransferase expression influence the antitumor efficacy of 2-chloroethyl-3-sarcosinamide- 1-nitrosourea in human tumor xenografts. J Pharmacol Exp Ther (2001) 0.78
Drug Information Center network: need, effectiveness, and cost justification. Drug Intell Clin Pharm (1987) 0.78
Polyadenylylation of reovirus proteins. Analysis of the RNA bound to structural proteins. J Biol Chem (1980) 0.77
T-cell recognition of an allogeneic RT1-Dbu class II MHC peptide. Immunol Lett (1994) 0.77
The rat RT.BM1 MHC class I cDNA shows a high level of sequence similarity to the mouse H-2T23d gene. Immunogenetics (1991) 0.76
Comparison of tissue factor pathway in human umbilical vein and adult saphenous vein endothelial cells: implications for newborn hemostasis and for laboratory models of endothelial cell function. Pediatr Res (1999) 0.76
Multiple cellular proteins are recognized by the adeno-associated virus Rep78 major regulatory protein and the amino-half of Rep78 is required for many of these interactions. Biochem Mol Biol Int (1997) 0.76
Effect of pH and nonphysiological salt concentrations on human immunodeficiency virus-1 protease dimerization. Biochem Cell Biol (1995) 0.76
Polyadenylylation of proteins in reovirions. Proc Natl Acad Sci U S A (1979) 0.76
Experimental ulcerative herpetic keratitis. II. Influence of topical corticosteroid in immunised rabbits. Br J Ophthalmol (1981) 0.75
Effects of retinoic acid combined with interferon-gamma on the expression of major-histocompatibility-complex molecules and intercellular adhesion molecule-1 in human cervical cancer. Int J Cancer (1998) 0.75
Experimental ulcerative herpetic keratitis. III. Evaluation of hyperimmune gammaglobulin therapy. Br J Ophthalmol (1981) 0.75
Continuous assay of the hydrolytic activity of human immunodeficiency virus-1 protease. Anal Biochem (1992) 0.75
[Expression of extraneuronal monoamine transporter gene and DNA repair gene vis-à-vis with antitumor efficacy of SarCNU in human tumor xenografts]. Zhonghua Zhong Liu Za Zhi (2001) 0.75
[Anti-tumor efficacy of 2-chloroethyl-3-sarcosinamide-1-nitrosourea in a human lung cancer xenograft model with DNA repair gene expressions]. Zhongguo Fei Ai Za Zhi (2000) 0.75
Comparison of human umbilical vein and adult saphenous vein endothelial cells: implications for newborn hemostasis and for laboratory models of endothelial cell function. J Pediatr Hematol Oncol (2000) 0.75
Formation of N2,3-ethanoguanine in DNA after in vitro treatment with the therapeutic agent, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea. Carcinogenesis (1990) 0.75
In vitro methylation of adenosine residues in reovirus RNA. Virology (1978) 0.75
Balancing the clinical outcomes and economics associated with thromboembolic prophylaxis. Orthopedics (1996) 0.75
Upper airway obstruction in a llama caused by aberrant nasopharyngeal bots (Cephenemyia sp.). Vet Radiol Ultrasound (1997) 0.75
Energy cost of rehabilitation calisthenics. Phys Ther (1979) 0.75
Pharmacokinetics of cetamolol in hypertensive patients with normal and compromised renal function. J Clin Pharmacol (1988) 0.75
Therapeutic assessment of Slow-K and K-tab potassium chloride formulations in hypertensive patients treated with thiazide diuretics. Drug Intell Clin Pharm (1987) 0.75
The pharmacology of antiulcer drugs. DICP (1989) 0.75
Activation of reovirion-associated poly(A) polymerase and oligomer methylase by cofactor-dependent cleavage of mu polypeptides. Virology (1979) 0.75
Dialyzability and pharmacokinetics of indomethacin in adult patients with end-stage renal disease. Drug Intell Clin Pharm (1986) 0.75
The formation and enzymatic repair of DNA modifications caused by the haloethylnitrosoureas and related compounds. Nucleic Acids Symp Ser (1992) 0.75
Home-made jelly duplicator. Trop Doct (1987) 0.75
Utilizing education infrastructure for primary health care. Trop Doct (1988) 0.75
Terfenadine, a nonsedating antihistamine. Drug Intell Clin Pharm (1985) 0.75
The comparative bioavailability of liquid, wax-matrix, and microencapsulated preparations of potassium chloride. J Clin Pharmacol (1986) 0.75
Reye syndrome and salicylates: update for pharmacists. Am Pharm (1986) 0.75
Balancing the clinical outcomes and economics associated with thromboembolic prophylaxis. Orthopedics (1996) 0.75
Localization of tenascin in uterine sarcomas and partially transformed endometrial stromal cells. Pathobiology (1993) 0.75
Fixed dilated pupils following cardiac surgery. Anaesthesia (1987) 0.75
The NICU experience in retrospect. Clin Pediatr (Phila) (1988) 0.75
Safety and acid-suppressant properties of histamine2-receptor antagonists for the prevention of stress-related mucosal damage in critical care patients. DICP (1989) 0.75
Preliminary studies concerning the culture of cryopreserved bovine corneal endothelium. Curr Eye Res (1982) 0.75